TrialAdvances in therapy2022

Safety Findings in Lasmiditan as a Novel Acute Treatment of Migraine in Chinese Patients: A Post Hoc Analysis of the Randomized Controlled Phase 3 CENTURION Trial.

Jiying Zhou et al.PubMed ↗Publisher ↗

No numbers read from the abstract.